18 completed, 1 terminated. 19 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 18, Terminated 1 |
Follow ipragliflozin: new trials by email Literature Review of ipragliflozin trials Research Report on ipragliflozin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin Ipragliflozin, Sitagliptin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Seoul National University Bundang Hospital | 170 | 2017-04-25 | 2022-10-04 |
| A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus ipragliflozin, Placebo, Insulin Therapy - Type 1 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 175 | 2016-08-29 | 2024-11-12 |
| A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Ipragliflozin L-proline, Metformin, Placebo - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Europe B.V. | 268 | 2016-05-11 | 2024-11-12 |
| Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843) Ipragliflozin, Placebo, Sitagliptin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 143 | 2015-11-09 | 2018-09-04 |
| Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842) Sitagliptin, Placebo, Ipragliflozin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 141 | 2015-11-05 | 2018-08-31 |
| Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849) Ipragliflozin, Sitagliptin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 77 | 2015-10-26 | 2018-09-04 |
| A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin ASP1941, Placebo - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Korea, Inc. | 143 | 2015-06-22 | 2024-11-12 |
| A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients ipragliflozin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 174 | 2012-05-25 | 2024-11-08 |
| A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus ASP1941, acarbose, Placebo - Type II Diabetes Mellitus | Phase 3 | Terminated | Astellas Pharma Inc | 46 | 2012-04-23 | 2024-11-12 |
| A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients ASP1941, metformin, Placebo - Type II Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 171 | 2011-11-28 | 2024-11-12 |
| A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment ASP1941, placebo - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 165 | 2011-01-18 | 2025-05-22 |
| A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients ipragliflozin, nateglinide - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 122 | 2011-01-15 | 2025-05-30 |
| A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients ipragliflozin, alpha glucosidase inhibitor - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 113 | 2010-10-21 | 2025-05-30 |
| A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients ipragliflozin, DPP-4 inhibitor - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 106 | 2010-10-21 | 2025-05-30 |
| A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients ipragliflozin, Placebo, Sulfonylurea - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 243 | 2010-09-17 | 2025-05-30 |
| A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients ipragliflozin, Placebo, Pioglitazone - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 152 | 2010-09-15 | 2025-05-30 |
| A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients ipragliflozin, Placebo, metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 168 | 2010-05-15 | 2025-05-30 |
| A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients ipragliflozin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 182 | 2010-01-14 | 2025-05-30 |
| A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients ipragliflozin, placebo - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 130 | 2010-01-13 | 2025-05-30 |
Diabetes Mellitus, Type 2 (18) · Diabetes Mellitus (9) · Glycosuria (2) · Diabetes Mellitus, Type 1 (1) · Renal Insufficiency (1)
Astellas Pharma Inc (13) · Merck Sharp & Dohme LLC (3) · Astellas Pharma Europe B.V. (1) · Astellas Pharma Korea, Inc. (1) · Seoul National University Bundang Hospital (1)
Japan (11) · South Korea (4) · Taiwan (2) · Russia (1)
Soo Lim (1)